A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia.

Trial Profile

A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2018

At a glance

  • Drugs Ofatumumab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPLEMENT 2
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 13 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 30 Nov 2017 This trial has been completed in Greece (End date: 2017-10-25).
    • 23 Nov 2017 This trial has been completed in Bulgaria (End Date:2017-10-25).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top